Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Written by ClinicalTrials.gov

Category: Muscle Diseases

Published: 12 August 2011

Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338; Biological: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2011

Details: Last Updated: 12 August 2011

Find, Use, Share, Expand Orthopaedic Information

Improving orthopaedic care, education and research using Internet technologies